Interstitial Lung Disease and Lung Transplantation

Sarah O'Beirne; Ian P Counihan; Michael P Keane

doi:10.1055/s-0030-1249110

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2010; 31(2): 139-146
DOI: 10.1055/s-0030-1249110

Interstitial Lung Disease and Lung Transplantation

Sarah O'Beirne¹ ^, ² , Ian P. Counihan¹ ^, ² , Michael P. Keane¹ ^, ²

¹Department of Medicine and Medical Specialties, School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
²Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland

Abstract

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias and carries the worst prognosis. Currently the best treatment option is lung transplantation. Historically patients with IPF had poor outcomes following referral for lung transplant due to high waiting-list mortality. The introduction of the lung allocation score in the United States in 2005 has reduced 1 year waiting-list mortality from 21% to 11% and also led to IPF becoming the most common diagnosis for lung transplantation. Although prioritizing all patients with IPF on the waiting list has led to a dramatic decline in waiting-list mortality, further improvements may be made by prioritizing which patients with IPF should be transplanted, with an emphasis on 6-minute walk testing, biomarkers, and the presence of pulmonary hypertension rather than traditional pulmonary function tests. The choice of surgical procedure and the prediction and management of posttransplant complications may also influence long-term outcomes.

KEYWORDS

Lung - fibrosis - transplant

Volltext

Referenzen

REFERENCES

1 Table 12.4a Transplant Recipient Characteristics, 1998 to 2007 Recipients of Deceased Donor Lungs. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998–2007. In: Organ Procurement and Transplantation Network; 2008 http://optn.transplant.hrsa.gov/ar2008/Chapter_VI_AR_CD.htm?cp=7#14
2 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias . This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165(2) 277-304
3 Bjoraker J A, Ryu J H, Edwin M K et al.. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 157 199-203
4 du Bois R, King Jr T E. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax. 2007; 62 1008-1012
5 Thabut G, Mal H, Castier Y et al.. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003; 126 469-475
6 Chen H, Shiboski S C, Golden J A et al.. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009; 180 468-474
7 Haider Y, Yonan N, Mogulkoc N, Carroll K B, Egan J J. Bronchiolitis obliterans syndrome in single lung transplant recipients—patients with emphysema versus patients with idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2002; 21 327-333
8 Orens J B, Estenne M, Arcasoy S Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25 745-755
9 Collard H R, King Jr T E, Bartelson B B, Vourlekis J S, Schwarz M I, Brown K K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168 538-542
10 Flaherty K R, Mumford J A, Murray S et al.. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168 543-548
11 King Jr T E, Safrin S, Starko K M et al.. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127 171-177
12 Lederer D J, Arcasoy S M, Wilt J S, D'Ovidio F, Sonett J R, Kawut S M. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174 659-664
13 Lama V N, Flaherty K R, Toews G B et al.. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168 1084-1090
14 Boon K, Bailey N W, Yang J et al.. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One. 2009; 4 e5134
15 Rosas I O, Richards T J, Konishi K et al.. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5 e93
16 Prasse A, Probst C, Bargagli E et al.. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179 717-723
17 Kinder B W, Brown K K, McCormack F X et al.. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009; 135 1557-1563
18 Meyers B F, Lynch J P, Trulock E P, Guthrie T, Cooper J D, Patterson G A. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg. 2000; 120 99-107
19 Charman S C, Sharples L D, McNeil K D, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant. 2002; 21 226-232
20 Meyer D M, Edwards L B, Torres F, Jessen M E, Novick R J. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg. 2005; 79 950-957, discussion 957–958
21 Nwakanma L U, Simpkins C E, Williams J A et al.. Impact of bilateral versus single lung transplantation on survival in recipients 60 years of age and older: analysis of United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2007; 133 541-547
22 Keating D, Levvey B, Kotsimbos T et al.. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009; 41 289-291
23 Weiss E S, Allen J G, Merlo C A, Conte J V, Shah A S. Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis. Ann Thorac Surg. 2009; 88 1616-1625 discussion 1625-1626
24 Lettieri C J, Nathan S D, Barnett S D, Ahmad S, Shorr A F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129 746-752
25 Arcasoy S M, Christie J D, Ferrari V A et al.. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167 735-740
26 Nadrous H F, Pellikka P A, Krowka M J et al.. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005; 128 2393-2399
27 Zisman D A, Lynch III J P, Strieter R M et al.. Pulmonary arterial hypertension (PAH) is common in patients with idiopathic pulmonary fibrosis referred for lung transplantation [abstract]. Am J Respir Crit Care Med. 2005; 2 A123
28 Gagermeier J, Dauber J H, Gibson K, Richards T, Kaminski N. Prevalence of secondary pulmonary hypertension in patients with idiopathic pulmonary fibrosis [abstract]. Proc Am Thorac Soc. 2005; 2 A205
29 Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration. 1983; 44 118-127
30 Shorr A F, Cors C, Lettieri C J, Nathan S. Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology and clinical correlates. Chest. 2005; 128S 218S
31 Kawut S M, O'Shea M K, Bartels M N, Wilt J S, Sonett J R, Arcasoy S M. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med. 2005; 99 1431-1439
32 Lederer D J, Caplan-Shaw C E, O'Shea M K et al.. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant. 2006; 6 398-403
33 Hamada K, Nagai S, Tanaka S et al.. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007; 131(3) 650-656
34 King Jr T E, Tooze J A, Schwarz M I, Brown K R, Cherniack R M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001; 164(7) 1171-1181
35 Whelan T P, Dunitz J M, Kelly R F et al.. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005; 24 1269-1274
36 Whitson B A, Nath D S, Johnson A C et al.. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006; 131 73-80
37 Bando K, Keenan R J, Paradis I L et al.. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg. 1994; 58 1336-1342
38 Daud S A, Yusen R D, Meyers B F et al.. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007; 175 507-513
39 Arcasoy S M, Fisher A, Hachem R R, Scavuzzo M, Ware L B. ISHLT Working Group on Primary Lung Graft Dysfunction . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, V: Predictors and outcomes. J Heart Lung Transplant. 2005; 24 1483-1488
40 Kozower B D, Meyers B F, Smith M A et al.. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. J Thorac Cardiovasc Surg. 2008; 135 166-171
41 Meyer D M, Bennett L E, Novick R J, Hosenpud J D. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation. Chest. 2000; 118 1255-1262
42 de Perrot M, Bonser R S, Dark J ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, III: Donor-related risk factors and markers. J Heart Lung Transplant. 2005; 24 1460-1467
43 Lee J, Kuntz C L, Hadjiliadis D et al.. Risk factors for primary graft dysfunction after lung transplantation [abstract]. Am J Respir Crit Care Med. 2008; 177 A396
44 Fiser S M, Kron I L, McLendon Long S, Kaza A K, Kern J A, Tribble C G. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant. 2001; 20 631-636
45 Barr M L, Kawut S M, Whelan T P ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, IV: Recipient-related risk factors and markers. J Heart Lung Transplant. 2005; 24 1468-1482
46 Bobadilla J L, Love R B, Jankowska-Gan E et al.. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med. 2008; 177 660-668
47 Nathan S D, Barnett S D, Urban B A, Nowalk C, Moran B R, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest. 2003; 123 1758-1763
48 Kelly K, Hertz M I. Obliterative bronchiolitis. Clin Chest Med. 1997; 18 319-338
49 Stewart S, Fishbein M C, Snell G I et al.. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007; 26 1229-1242
50 Estenne M, Maurer J R, Boehler A et al.. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002; 21 297-310
51 Burton C M, Carlsen J, Mortensen J, Andersen C B, Milman N, Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2007; 26 681-686
52 El-Gamel A, Awad M R, Hasleton P S et al.. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant. 1999; 18 517-523
53 El-Gamel A, Sim E, Hasleton P et al.. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant. 1999; 18 828-837
54 Snyder L D, Hartwig M G, Ganous T et al.. Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant. J Heart Lung Transplant. 2006; 25 1330-1335
55 Hodge S, Holmes M, Banerjee B et al.. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant. 2009; 9 727-733

Michael P KeaneM.D.

Department of Respiratory Medicine, St. Vincent's University Hospital

Elm Park, Dublin 4, Ireland

eMail: michael.p.keane@ucd.ie